TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA

Roberto Rivera Luna, R. Cardenas-Cardos, C. Meza-Coria, C. Leal-Leal, A. Martinez-Avalos, J. Ruano-Aguilar, M. Bonilla-Majano, A. Castellanos-Toledo, F. Carrete-Ramirez, A. Navarro-Alegria, T. Lanche-Guevara, A. Bravo-Lindoro, C. Ridaura-Sanz, A. Romero-Sandoval, M. A. Olavarria-Vega

Resultado de la investigación: Contribución a una revistaArtículo

1 Cita (Scopus)

Resumen

A 4 years 9 month old male child with the diagnosis of acute non-lymphoblastic leukemia M4 (ANLL) on bone marrow remission, that was submitted to an autologous bone marrow transplant (ABMT) with bone marrow purge is reported. At the time of the referral, the patient had a previous history of a bone marrow relapse. Prior to an extensive evaluation the patient was submitted to a ABMT, the purging treatment consisted in the usage in-vitro of VP16 and methylprednisolone. These active cytotoxic agents and the patient's bone marrow buffy coat cells (hematopoietic stem cells) were combined. After tumor cell-drug interactions occurred, the cell suspension was washed free of excess drug. Tumor depleted marrow was cryopreserved in liquid nitrogen. Meanwhile the patient was treated with ablative therapy with busulfan and cyclophosphamide with mesna uroprotection for a total of 8 days, follow by 1 day rest and at the 10th day infusion of the bone marrow. Cellularity and viability of the stem cells were measured before and after cryopreservation. The patient's tolerance to the chemotherapy program was excellent with almost nil toxicity, except for the complication of a septicemia by Candida tropicalis which was succesfully treated with amphotericin B. We consider that the bone marrow engrafted on the basis of the leukocyte and platelet rising count under 35 days after the bone was infused. This is the first report in the Mexican literature of a child with ANLL submitted to a ABMT and bone marrow purging. The patient is in continuous complete remission at 9 months from marrow transplant, we consider this therapeutic approach might be an alternative after a child with ANLL is on first remission.

Idioma originalEspañol
Páginas (desde-hasta)601-607
Número de páginas7
PublicaciónBoletin Medico del Hospital Infantil de Mexico
Volumen51
N.º9
EstadoPublicada - 1 ene 1994

Huella dactilar

Acute Myeloid Leukemia
Bone Marrow
Transplants
Bone Marrow Purging
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
In Vitro Techniques
Mesna
Candida tropicalis
Glycocalyx
Bone and Bones
Busulfan
Cryopreservation
Cytotoxins
Methylprednisolone
Amphotericin B
Hematopoietic Stem Cells
Platelet Count
Drug Interactions
Cell Communication

Palabras clave

  • acute nonlymphoblastic leukemia
  • autologous bone marrow transplant
  • treatment

Citar esto

Rivera Luna, R., Cardenas-Cardos, R., Meza-Coria, C., Leal-Leal, C., Martinez-Avalos, A., Ruano-Aguilar, J., ... Olavarria-Vega, M. A. (1994). TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA. Boletin Medico del Hospital Infantil de Mexico, 51(9), 601-607.
Rivera Luna, Roberto ; Cardenas-Cardos, R. ; Meza-Coria, C. ; Leal-Leal, C. ; Martinez-Avalos, A. ; Ruano-Aguilar, J. ; Bonilla-Majano, M. ; Castellanos-Toledo, A. ; Carrete-Ramirez, F. ; Navarro-Alegria, A. ; Lanche-Guevara, T. ; Bravo-Lindoro, A. ; Ridaura-Sanz, C. ; Romero-Sandoval, A. ; Olavarria-Vega, M. A. / TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA. En: Boletin Medico del Hospital Infantil de Mexico. 1994 ; Vol. 51, N.º 9. pp. 601-607.
@article{38eb4cb0b43049a1b9336e53b991b9a1,
title = "TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA",
abstract = "A 4 years 9 month old male child with the diagnosis of acute non-lymphoblastic leukemia M4 (ANLL) on bone marrow remission, that was submitted to an autologous bone marrow transplant (ABMT) with bone marrow purge is reported. At the time of the referral, the patient had a previous history of a bone marrow relapse. Prior to an extensive evaluation the patient was submitted to a ABMT, the purging treatment consisted in the usage in-vitro of VP16 and methylprednisolone. These active cytotoxic agents and the patient's bone marrow buffy coat cells (hematopoietic stem cells) were combined. After tumor cell-drug interactions occurred, the cell suspension was washed free of excess drug. Tumor depleted marrow was cryopreserved in liquid nitrogen. Meanwhile the patient was treated with ablative therapy with busulfan and cyclophosphamide with mesna uroprotection for a total of 8 days, follow by 1 day rest and at the 10th day infusion of the bone marrow. Cellularity and viability of the stem cells were measured before and after cryopreservation. The patient's tolerance to the chemotherapy program was excellent with almost nil toxicity, except for the complication of a septicemia by Candida tropicalis which was succesfully treated with amphotericin B. We consider that the bone marrow engrafted on the basis of the leukocyte and platelet rising count under 35 days after the bone was infused. This is the first report in the Mexican literature of a child with ANLL submitted to a ABMT and bone marrow purging. The patient is in continuous complete remission at 9 months from marrow transplant, we consider this therapeutic approach might be an alternative after a child with ANLL is on first remission.",
keywords = "acute nonlymphoblastic leukemia, autologous bone marrow transplant, treatment",
author = "{Rivera Luna}, Roberto and R. Cardenas-Cardos and C. Meza-Coria and C. Leal-Leal and A. Martinez-Avalos and J. Ruano-Aguilar and M. Bonilla-Majano and A. Castellanos-Toledo and F. Carrete-Ramirez and A. Navarro-Alegria and T. Lanche-Guevara and A. Bravo-Lindoro and C. Ridaura-Sanz and A. Romero-Sandoval and Olavarria-Vega, {M. A.}",
year = "1994",
month = "1",
day = "1",
language = "Espa{\~n}ol",
volume = "51",
pages = "601--607",
journal = "Boletin Medico del Hospital Infantil de Mexico",
issn = "0539-6115",
publisher = "Hospital Infantil de Mexico Federico Gomez",
number = "9",

}

Rivera Luna, R, Cardenas-Cardos, R, Meza-Coria, C, Leal-Leal, C, Martinez-Avalos, A, Ruano-Aguilar, J, Bonilla-Majano, M, Castellanos-Toledo, A, Carrete-Ramirez, F, Navarro-Alegria, A, Lanche-Guevara, T, Bravo-Lindoro, A, Ridaura-Sanz, C, Romero-Sandoval, A & Olavarria-Vega, MA 1994, 'TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA', Boletin Medico del Hospital Infantil de Mexico, vol. 51, n.º 9, pp. 601-607.

TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA. / Rivera Luna, Roberto; Cardenas-Cardos, R.; Meza-Coria, C.; Leal-Leal, C.; Martinez-Avalos, A.; Ruano-Aguilar, J.; Bonilla-Majano, M.; Castellanos-Toledo, A.; Carrete-Ramirez, F.; Navarro-Alegria, A.; Lanche-Guevara, T.; Bravo-Lindoro, A.; Ridaura-Sanz, C.; Romero-Sandoval, A.; Olavarria-Vega, M. A.

En: Boletin Medico del Hospital Infantil de Mexico, Vol. 51, N.º 9, 01.01.1994, p. 601-607.

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA

AU - Rivera Luna, Roberto

AU - Cardenas-Cardos, R.

AU - Meza-Coria, C.

AU - Leal-Leal, C.

AU - Martinez-Avalos, A.

AU - Ruano-Aguilar, J.

AU - Bonilla-Majano, M.

AU - Castellanos-Toledo, A.

AU - Carrete-Ramirez, F.

AU - Navarro-Alegria, A.

AU - Lanche-Guevara, T.

AU - Bravo-Lindoro, A.

AU - Ridaura-Sanz, C.

AU - Romero-Sandoval, A.

AU - Olavarria-Vega, M. A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - A 4 years 9 month old male child with the diagnosis of acute non-lymphoblastic leukemia M4 (ANLL) on bone marrow remission, that was submitted to an autologous bone marrow transplant (ABMT) with bone marrow purge is reported. At the time of the referral, the patient had a previous history of a bone marrow relapse. Prior to an extensive evaluation the patient was submitted to a ABMT, the purging treatment consisted in the usage in-vitro of VP16 and methylprednisolone. These active cytotoxic agents and the patient's bone marrow buffy coat cells (hematopoietic stem cells) were combined. After tumor cell-drug interactions occurred, the cell suspension was washed free of excess drug. Tumor depleted marrow was cryopreserved in liquid nitrogen. Meanwhile the patient was treated with ablative therapy with busulfan and cyclophosphamide with mesna uroprotection for a total of 8 days, follow by 1 day rest and at the 10th day infusion of the bone marrow. Cellularity and viability of the stem cells were measured before and after cryopreservation. The patient's tolerance to the chemotherapy program was excellent with almost nil toxicity, except for the complication of a septicemia by Candida tropicalis which was succesfully treated with amphotericin B. We consider that the bone marrow engrafted on the basis of the leukocyte and platelet rising count under 35 days after the bone was infused. This is the first report in the Mexican literature of a child with ANLL submitted to a ABMT and bone marrow purging. The patient is in continuous complete remission at 9 months from marrow transplant, we consider this therapeutic approach might be an alternative after a child with ANLL is on first remission.

AB - A 4 years 9 month old male child with the diagnosis of acute non-lymphoblastic leukemia M4 (ANLL) on bone marrow remission, that was submitted to an autologous bone marrow transplant (ABMT) with bone marrow purge is reported. At the time of the referral, the patient had a previous history of a bone marrow relapse. Prior to an extensive evaluation the patient was submitted to a ABMT, the purging treatment consisted in the usage in-vitro of VP16 and methylprednisolone. These active cytotoxic agents and the patient's bone marrow buffy coat cells (hematopoietic stem cells) were combined. After tumor cell-drug interactions occurred, the cell suspension was washed free of excess drug. Tumor depleted marrow was cryopreserved in liquid nitrogen. Meanwhile the patient was treated with ablative therapy with busulfan and cyclophosphamide with mesna uroprotection for a total of 8 days, follow by 1 day rest and at the 10th day infusion of the bone marrow. Cellularity and viability of the stem cells were measured before and after cryopreservation. The patient's tolerance to the chemotherapy program was excellent with almost nil toxicity, except for the complication of a septicemia by Candida tropicalis which was succesfully treated with amphotericin B. We consider that the bone marrow engrafted on the basis of the leukocyte and platelet rising count under 35 days after the bone was infused. This is the first report in the Mexican literature of a child with ANLL submitted to a ABMT and bone marrow purging. The patient is in continuous complete remission at 9 months from marrow transplant, we consider this therapeutic approach might be an alternative after a child with ANLL is on first remission.

KW - acute nonlymphoblastic leukemia

KW - autologous bone marrow transplant

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0028143951&partnerID=8YFLogxK

M3 - Artículo

AN - SCOPUS:0028143951

VL - 51

SP - 601

EP - 607

JO - Boletin Medico del Hospital Infantil de Mexico

JF - Boletin Medico del Hospital Infantil de Mexico

SN - 0539-6115

IS - 9

ER -

Rivera Luna R, Cardenas-Cardos R, Meza-Coria C, Leal-Leal C, Martinez-Avalos A, Ruano-Aguilar J y otros. TRASPLANTE AUTOLOGO DE MEDULA OSEA Y TRATAMIENTO IN VITRO EN LEUCEMIA AGUDA NO LINFOBLASTICA. Boletin Medico del Hospital Infantil de Mexico. 1994 ene 1;51(9):601-607.